Contains Nonbinding Recommendations
19
REFERENCES
Abrams J, B Conley, M Mooney, J Zwiebel, A Chen, JJ Welch, N Takebe, S Malik, L McShane,
E Korn, M Williams, L Staudt, and J Doroshow, 2014, National Cancer Institute’s Precision
Medicine Initiatives for the New National Clinical Trials Network, Am Soc Clin Oncol Educ
Book, 34:71–76.
Herbst RS, DR Gandara, FR Hirsch, MW Redman, M LeBlanc, PC Mack, LH Schwartz, E
Vokes, SS Ramalingam, JD Bradley, D Sparks, Y Zhou, C Miwa, VA Miller, R Yelensky, Y Li,
JD Allen, EV Sigal, D Wholley, CC Sigman, GM Blumenthal, S Malik, GJ Kelloff, JS Abrams,
CD Blanke, and VA Papadimitrakopoulou, 2015, Lung Master Protocol (Lung-MAP)—A
Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung
Cancer: SWOG S1400, Clin Cancer Res, 21(7):1514–1524.
Hyman DM, I Puzanov, V Subbiah, JE Faris, I Chau, J-Y Blay, J Wolf, NS Raje, EL Diamond,
A Hollebecque, R Gervais, ME Elez-Fernandez, A Italiano, R-D Hofheinz, M Hildago, E Chan,
M Schuler, SF Lasserre, M Makrutzki, F Sirzen, ML Veronese, J Tabernero, and J Baselga,
2015, Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations, N Engl J
Med, 373(8):726–736.
Kim ES, RS Herbst, II Wistuba, JJ Lee, GR Blumenschein Jr., A Tsao, DJ Stewart, ME Hicks, J
Erasmus Jr., S Gupta, CM Alden, S Liu, X Tang, FR Khuri, HT Tran, BE Johnson, JV Heymach,
L Mao, F Fossella, MS Kies, V Papadimitrakopoulou, SE Davis, SM Lippman, and WK Hong,
2011, The BATTLE Trial: Personalizing Therapy for Lung Cancer, Cancer Discov, 1(1): 44–53.
Simon R, 1989, Optimal Two-Stage Designs for Phase II Clinical Trials, Control Clin Trials,
10(1):1–10.
Woodcock, J and LM LaVange, 2017, Master Protocols to Study Multiple Therapies, Multiple
Diseases, or Both, N Engl J Med, 377(1):62–70.